HomeCompareVPRO vs KO

VPRO vs KO: Dividend Comparison 2026

VPRO yields 10000000.00% · KO yields 2.71%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VPRO wins by $4.762052817831319e+46M in total portfolio value
10 years
VPRO
VPRO
● Live price
10000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.762052817831319e+46M
Annual income
$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00
Full VPRO calculator →
KO
The Coca-Cola Company
● Live price
2.71%
Share price
$76.05
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,323.37
Full KO calculator →

Portfolio growth — VPRO vs KO

📍 VPRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVPROKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VPRO + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VPRO pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VPRO
Annual income on $10K today (after 15% tax)
$850,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
KO
Annual income on $10K today (after 15% tax)
$230.24/yr
After 10yr DRIP, annual income (after tax)
$3,674.86/yr
At 15% tax rate, VPRO beats the other by $40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VPRO + KO for your $10,000?

VPRO: 50%KO: 50%
100% KO50/50100% VPRO
Portfolio after 10yr
$2.3810264089156593e+46M
Annual income
$23,809,795,714,437,028,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

VPRO
No analyst data
Altman Z
-0.9
Piotroski
2/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.6% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VPRO buys
0
KO buys
13
PoliticianChamberTickerTypeAmountDate
Markwayne Mullin🏛 Senate$KO▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$KO▲ Buy$15,001 - $50,0002025-12-29
Lloyd Doggett🏢 House$KO▲ Buy$1,001 - $15,0002025-12-15
Sheldon Whitehouse🏛 Senate$KO▲ Buy$1,001 - $15,0002025-11-21
Sheldon Whitehouse🏛 Senate$KO▲ Buy$1,001 - $15,0002025-11-21
Julia Letlow🏢 House$KO▲ Buy$1,001 - $15,0002025-11-03
Lisa McClain🏢 House$KO▲ Buy$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$KO▲ Buy$1,001 - $15,0002025-09-25
Val Hoyle🏢 House$KO▼ Sell$1,001 - $15,0002025-09-23
Ro Khanna🏢 House$KO▼ Sell$1,001 - $15,0002025-09-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVPROKO
Forward yield10000000.00%2.71%
Annual dividend / share$2.00$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$4.762052817831319e+46M$34.1K
Annual income after 10y$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$4,323.37
Total dividends collected$4.762046689458665e+46M$15.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: VPRO vs KO ($10,000, DRIP)

YearVPRO PortfolioVPRO Income/yrKO PortfolioKO Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$10,847$336.70+$1000.00MVPRO
2$93,460,013,936,683$93,458,943,925,233.62$11,832$431.92+$93460013.92MVPRO
3$8,163,259,573,940,183,000$8,163,159,571,725,270,000.00$12,992$557.22+$8163259573940.17MVPRO
4$666,373,880,559,373,300,000,000$666,365,145,871,629,100,000,000.00$14,379$723.66+$666373880559373312.00MVPRO
5$50,838,057,311,279,720,000,000,000,000$50,837,344,291,227,520,000,000,000,000.00$16,059$947.18+$5.083805731127972e+22MVPRO
6$3,624,737,622,195,432,400,000,000,000,000,000$3,624,683,225,474,109,500,000,000,000,000,000.00$18,129$1,251.14+$3.6247376221954326e+27MVPRO
7$241,535,451,261,763,920,000,000,000,000,000,000,000$241,531,572,792,508,160,000,000,000,000,000,000,000.00$20,724$1,670.45+$2.4153545126176394e+32MVPRO
8$15,041,872,435,857,020,000,000,000,000,000,000,000,000,000$15,041,613,992,924,168,000,000,000,000,000,000,000,000,000.00$24,040$2,258.40+$1.504187243585702e+37MVPRO
9$875,466,765,540,973,800,000,000,000,000,000,000,000,000,000,000$875,450,670,737,467,500,000,000,000,000,000,000,000,000,000,000.00$28,364$3,098.25+$8.754667655409739e+41MVPRO
10$47,620,528,178,313,184,000,000,000,000,000,000,000,000,000,000,000,000$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$34,134$4,323.37+$4.762052817831319e+46MVPRO

VPRO vs KO: Complete Analysis 2026

VPROStock

Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies. The company's contractual work activities include cloning, sequencing, purifying, developing, validating, and producing biopharmaceutical products and sub-products. It has operations in Canada, the United Kingdom, and Malaysia. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company is based in San Jose, California. Viropro Inc. is a subsidiary of Alpha Biologics Limited.

Full VPRO Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this VPRO vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VPRO vs SCHDVPRO vs JEPIVPRO vs OVPRO vs MAINVPRO vs PEPVPRO vs PGVPRO vs JNJVPRO vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.